Comparison of MyStar DoseCoach to routine titration in Adult Patients with Type 2 Diabetes Mellitus using Toujeo

Phase 1

Conditions: Type 2 diabetes mellitus
MedDRA version: 18.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disorders
Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

Registration Number: EUCTR2014-004533-13-DE

Lead Sponsor: Sanofi-aventis recherche & développement

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 151

Inclusion Criteria

Patients with type 2 diabetes mellitus diagnosed at least one year before the screening visit.
Patients who are insulin naïve (and considered by the investigator to be appropriate candidates for basal insulin therapy), or treated with basal insulin as their only insulin.
HbA1c between 7.5% and 11% (inclusive) at screening.
Fasting SMPG >130 mg/dL at first screening and FSMPG >130 mg/dL at randomization.
Signed informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 111
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 37

Exclusion Criteria

Aged <18 years.
Diabetes other than type 2 diabetes mellitus.
MyStar DoseCoach device is not appropriate for the patient or use of
device is otherwise contraindicated (in the opinion of the Investigator).
Conditions/situations that are contraindications or off-label use
XML File Identifier: BFURztnmICdH90SHcWgWTsI/A8k=
Page 11/24
according to Summary of Product
Characteristics (SmPCs) of Oral Anti-Diabetes Drugs (OADs) and/or GLP-
1 receptor agonists when applicable (prescribed), or insulin glargine and
as defined in the national product label.
Patients not on stable dose of glucose lowering therapy including OADs,
GLP-1 receptor agonists, or basal insulin therapy, for the last 3 months
(stable basal insulin therapy defined as maximum change in insulin dose
of +/- 20%).
Patients using mealtime insulin (short acting analogue, human regular
insulin or premix insulin) for more than 10 days in the last 3 months
before screening visit.
Patients with hypoglycemia unawareness.
Patients with severe hypoglycemia in the past 90 days.
Hospitalization in the past 30 days.
Use of systemic glucocorticoids (excluding topical application or inhaled
forms) for one week or more within 90 days prior to the time of
screening.
Unable to meet specific protocol requirements (eg, inability to perform
blood glucose measurements, manage their own insulin glargine
administration, or deemed unlikely to safely manage titration based on
guidance by their health care provider or HCP, etc.), because of a
medical condition or because the patient is under legal guardianship.
-Patients with cognitive disorders, dementia, or any neurologic disorder
that would affect a patient's
ability to participate in the study, including the inability to understand
study requirements or to give
complete information about adverse symptoms.
-Conditions/situations such as:
-Patients with conditions/concomitant diseases precluding their safe
participation in this study
(eg, active malignant tumor, major systemic diseases, presence of
clinically significant diabetic
retinopathy or presence of macular edema likely to require treatment
within the study period, etc.),
-Patients unable to fully understand study documents and to complete
them. Patients who have a
caregiver together with whom they can fulfill all study requirements are
eligible,
-Patient is the Investigator or any Sub-Investigator, research assistant,
pharmacist, study
coordinator, other staff or relative thereof directly involved in the
conduct of the protocol.
-Within the last 3 months prior to screening: history of myocardial
infarction, unstable angina, acute
coronary syndrome, revascularization procedure, or stroke requiring
hospitalization.
-Severe or uncontrolled Congestive Heart Failure (New York Heart
Association [NYHA] functional
classification III and IV); or inadequately controlled hypertension at the
time of screening with a
resting systolic or diastolic blood pressure >180 mmHg or >95 mmHg,
respectively.
Pregnant or breast-feeding women or women who intend to become
pregnant during the study period as glycemic control may be unstable
and insulin doses may be variable during this period.
Women of childbearing potential (premenopausal, not surgically sterile
for at least 3 months prior to
the time of screening) must use an effective contraceptive method
throughout the study. Effective methods of contraception include barrier methods (in conjunction with

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: To demonstrate the non-inferiority of the MyStar DoseCoach (Long-acting Insulin Glargine Titration Meter) device-supported treat-to-target regimen relative to a routine titration regimen in the percentage of patients reaching glycemic target, ie, with a mean fasting self-monitored plasma glucose (FSMPG) value within the target range of 90-130 mg/dL (5.0-7.2 mmol/L) without a severe hypoglycemic episode during the 16-week on-treatment period.;Secondary Objective: To assess the efficacy, safety and adherence/satisfaction of MyStar DoseCoach ;Primary end point(s): Percentage of patients reaching fasting SMPG target range 90- 130 mg/dL (5.0-7.2 mmol/L) at Week 16 (mean of the last 5 readings recorded over the last 2 weeks) without a severe hypoglycemic episode during the 16-week on-treatment period;Timepoint(s) of evaluation of this end point: Baseline to Week 16

Secondary Outcome Measures

Name	Time	Method

Related Trials